Replimune appoints former Genentech exec Michelle DiNapoli as chief commercial officer after accelerated melanoma approval

Replimune announced that Michelle DiNapoli will become its chief commercial officer, starting August 18. DiNapoli previously held senior roles at Genentech, where she led commercial operations.

The appointment follows the company's recent accelerated approval by the FDA for its melanoma therapy, marking a significant milestone for the biotech.

In a separate leadership change, Neumora reported that Paul Berns will step down from his role as chief executive officer, though his future involvement with the company was not detailed.

Both moves reflect ongoing executive reshuffling in the biotech sector as firms position themselves for commercial growth and strategic direction.